Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women

Osteoporosis International

Volumn 8, Issue 4, 1998, Pages 326-332

  Hart, D M ^a   Farish, E ^a   Fletcher, C D ^a   Barnes, J F ^a   Hart, H ^a   Nolan, D ^a   Spowart, K ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Bone mineral density; Hormone replacement therapy; Osteoporosis; Serum lipid profile

Indexed keywords

ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORETHISTERONE;

ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LONG TERM CARE; LUMBAR SPINE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BONE DENSITY; CHOLESTEROL; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 0031659024     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980050071     Document Type: Article

References (44)

1. Consensus Development Conference. Who are candidates for preventative and therapeutic therapy for osteoporosis? World Congress of Osteoporosis, Amsterdam, 1996.
2. Rozenbaum H, Birkhäuser MH. Consensus propositions. In: Rozenbaum H, Birkhäuser MH, editors. Menopause: European Consensus Development Conference, Montreaux, Switzerland, Paris. Editions ESKA, 1996:293-303.
3. Stevenson JC, Whitehead MJ, Postmenopausal osteoporosis. BMJ 1982;285:585-8.
4. Christiansen C, Christiansen MS, McNair PL, et al. Prevention of early postmenopausal bone loss: conducted 2-year study of 315 normal females. Eur J Clin Invest 1980;10:273-9.
5. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;ii:1151-3.
6. Eriksen EF, Kassem M, Langdahl B. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996;19(Suppl):S179-83.
7. Weiss NS, Ure CL, Ballard JH, et al Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
8. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
9. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 1987;317:1169-74.
10. Naessén T, Persson I, Adami H-O. Hormone replacement therapy and risk of first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
11. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5:23-9.
12. Christiansen C, Christiansen MS, Transbøl IB. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61
13. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 1997;277:543-7.
14. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
15. Zakaria FBP, Studd JWW. The outcome of different doses and routes of oestrogen therapy. Eur Menopause J 1996;3(Suppl):178-85.
16. Ryan PJ. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-8.
17. Rees M. On menstrual bleeding with hormone replacement therapy. Lancet 1994;343:250.
18. Ravnikar VA. Barriers for taking long-term hormone replacement therapy: Why do women not adhere to therapy? Eur Menopause J 1996;3(Suppl):90-3.
19. Staland B. Continuous treatment with natural oestrogens and progestogens: a method to avoid endometrial stimulation. Maturitas 1981;3:145-6.
20. Dören M, Reuther G, Minne HW, Schneider HPG. Superior compliance and efficiency of continuous combined oral oestrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995;173:1446-51.
21. Eiken P, Kokhoff N. Compliance with long-term oral hormonal replacement therapy. Maturitas 1995;22:97-103.
22. Christiansen C, Riis BJ. Five years with continuous combined oestrogen/progestogen therapy: effects on calcium metabolism, lipoproteins. and bleeding pattern. Br J Obstet Gynaecol 1990;97:1087-92.
23. Farish E, Fletcher CD, Dagen MM, et al. The effects on bone metabolism and bone density of continuous oestrogen/progestogen therapy with and without oestriol. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1987. Proceedings of the International Symposium on Osteoporosis. Osteopress, Denmark, 1987:539-41.
24. Farish E, Fletcher CD, Dagen MM, et al. Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/prosestogen therapy. Br J Obstet Gynaecol 1989;96:358-64.
25. Parish E, Fletcher CD, Barnes JF, Hart DM. Effects of four years continuous oestrogen/progestogen therapy on lipoprotein metabolism and bone density. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Osteopress. Denmark, 1990:1832-3.
26. Mazess RB Advances in total body and regional bone mineral measurement by dual-photon absorptiometry. In: Menczel et al., editors. Osteoporosis. New York: Wiley, 1982.
27. 153Gd) and dual energy x-ray absorptiometry (DEXA). Glasgow: Bone and Tooth Society, 1990
28. Farish E, Fletcher CD, Hart DM, Kitchener H, Sharpe GLM, A long-term study of the effects of norethisterone on lipoprotein metabolism in menopausal women. Clin Chim Acta 1983;132:193-8
29. Eyre J, Hammett F, Miller NE. A micro method for the rapid ultracentrifugal separation of human plasma high density lipoprotein subfractions HDL2 and HDL3. Clin Chim Acta 1981;114:225-31.
30. Pors Nielsen PS, Barenholdt O, Hermansen F, Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestogen treatment. Br J Obstet Gynaecol 1994;101:319-24.
31. Report of the National Cholesterol Education Program expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
32. Riggs BL, Melton MJ. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7.
33. Compston JE. HRT and osteoporosis. Br Med Bull 1992;48:309-44.
34. Eiken P, Kolthoff N, Pors Nielsen S. Effect of 10 years' hormone replacement in postmenopausal women. Bone 1996;19 (5 Suppl):S191-4.
35. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease in women: perspective from the Framingham study. Am Heart J 1987;114:413-9
36. Samsioe G, Astedt B. Does progestogen co-medication attenuate the cardiovascular benefits of oestrogens? In: Birkhäuser MH, Rozenbaum H, editors. Menopause: European Consensus Development Conference, Montreux. Switzerland. Paris: Editions ESKA. 1996:175-83.
37. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distribution in selected North American populations: the Lipid Research Clinics Prevalence Study Circulation 1980;61:302-15.
38. Stampfer MJ, Sacks FM, Simonetta, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
39. Falkeborn M, Persson I, Adarni HI, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
40. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1992;151:746-50.
41. Munk-Jensen N, Ulrich LG, Obel EB, et al. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994;171:132-8.
42. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59
43. Wren BG, Eden JA. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause 1996;3:4-12.
44. Butler RN, Collins KS, Meier DE, et al. Older women's health: clinical care in the postmenopausal years. Geriatrics 1995;50:33-41.